Browsing by Author "Salome Charalambous"
Now showing 1 - 16 of 16
- Results Per Page
- Sort Options
Item Description of adverse events among adult men following voluntary medical male circumcision Findings from a circumcision programme in two provinces of South AfricaE Muchiri; Salome Charalambous; S Ginindza; M Maraisane; Tintswalo Maringa; E et al; Candice Chetty-MakkanItem Does a youth intern programme strengthen HIV service delivery in South Africa An interrupted timeseries analysis(INT AIDS SOCIETY) D Tollefson; S Dasgupta; G Setswe; S Reeves; Salome Charalambous; E et alItem Exploring the promise and reality of wardbased primary healthcare outreach teams conducting TB household contact tracing in three districts of South AfricaCandice Chetty-Makkan; Daniel deSanto; R Lessels; Salome Charalambous; K Velen; S Makgopa; D Gumede; Katherine Fielding; Alison GrantItem Exploring the syndemic interaction between social environmental and structural contexts of HIV infection in perimining areas in South Africa A qualitative study(BMJ PUBLISHING GROUP) L Chimoyi; P Ndini; M Oladimeji; N Seatlholo; Salome Charalambous; E "et al"Item Feasibility and acceptability of the smart pillbox and medication label with differentiated care to support personcentered tuberculosis care among ASCENT trial participants A multicountry studyA Tadesse; Andrew Mganga; T Dube; Jason Alacapa; Salome Charalambous; E "et al"; Katherine FieldingItem HIV1 resupression on a firstline regimen despite the prescence of phenotypic drug resistance(Public Library of Science) Adriaan Basson; Salome Charalambous; Christopher Hoffmann; Lynn MorrisWe have previously reported on HIV-1 infected patients who fail anti-retroviral therapy but manage to re-suppress without a regimen change despite harbouring major drug resistance mutations. Here we explore phenotypic drug resistance in such patients in order to better understand this phenomenon. Patients (n = 71) failing a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen, but who subsequently re-suppressed on the same regimen, were assessed for HIV-1 genotypic drug resistance through Sanger sequencing. A subset (n =23) of these samples, as well as genotypically matched samples from patients who did not re-suppress (n = 19), were further assessed for phenotypic drug resistance in an in vitro single cycle assay. Half of the patients (n = 36/71, 51%) harboured genotypic drug resistance, with M184V(n=18/36,50%)andK103N(n=16/36,44%)being the most prevalent mutations. No significant difference in the median time to re-suppression (31–39 weeks) were observed for either group (p = 0.41). However, re-suppressors with mutant virus rebounded significantly earlier than those with wild-type virus (16 vs. 33 weeks; p = 0.014). Similar phenotypic drug resistance profiles were observed between patients who re-suppressed and patients who failed to re-suppress. While most remained susceptible to stavudine (d4T) and zidovudine (AZT), both groups showed a reduced susceptibility to 3TC and NNRTIs. HIV- 1 infected patients on an NNRTI-based regimen can achieve viral re-suppression on the same regimen despite harbouring viruses with genotypic and phenotypic drug resistance. However, re-suppression was less durable in those with resistance, reinforcing the importance of appropriate regimen choices, ongoing viral load monitoring and adherence counselling.Item HIV1 resupression on a firstline regimen despite the prescence of phenotypic drug resistanceAdriaan Basson; Salome Charalambous; Christopher Hoffmann; Lynn MorrisItem Human resource time commitments and associated costs of Community Caregiver outreach team operations in South Africa(PUBLIC LIBRARY SCIENCE) Rachel Mukora; R R Thompson; P Hippner; R Pelusa; M Mothibi; Salome Charalambous; E et alItem Impact of youth lay health workers on HIV service delivery in South Africa A pragmatic cluster randomized trial of the Youth Health Africa program(PUBLIC LIBRARY SCIENCE) D Tollefson; S Dasgupta; G Setswe; S Reeves; Salome Charalambous; Ann DuerrItem Its about time they taught us a qualitative study evaluating the barriers to finding and screening child contacts under five at risk for TB in Gauteng Province South Africa from the provider and caregiver perspectives(BIOMED CENTRAL LTD) Fadzai Munedzimwe; Candice Chetty-Makkan; Rachel Mukora; Salome Charalambous; K Turner; Violet ChihotaItem Lung outcomes and related risk factors in patients after SARSCoV2 infection a hospitalised singlecentre cohort from Johannesburg South AfricaN Glover; O Ivanova; F Sathar; F Riess; Colin Menezes; Sarah Van Blydenstein; Ismail Kalla; Salome Charalambous; E et alItem Qualitative study exploring the feasibility of using medication monitors and a differentiated care approach to support adherence among people receiving TB treatment in South Africa(BMJ PUBLISHING GROUP) Rachel Mukora; N Maraba; C Orrell; L Jennings; P Naidoo; E et al; Salome Charalambous; Candice Chetty-MakkanItem TB sequel incidence pathogenesis and risk factors of longterm medical and social sequelae of pulmonary TB a study protocolAndrea Rachow; Olena Ivanova; R Wallis; Salome Charalambous; I Jani; Denis Evans; Ian Sanne; Gavin Churchyard; E et alItem Transitional community adherence support for people leaving incarceration in South Africa a pragmatic openlabel randomised controlled trialT Mabuto; D Woznica; P Ndini; D Moyo; Salome Charalambous; E "et al"Item Treatment adherence and clinical outcomes amongst in people with drugsusceptible tuberculosis using medication monitor and differentiated care approach compared with standard of care in South Africa a cluster randomized trialSalome Charalambous; N Maraba; L Jennings; I Rabothata; D Cogill; Rachel Mukora; E et al; Katherine FieldingItem Youth Preferences for HIV Testing in South Africa Findings from the Youth Action for Health YA4H Study Using a Discrete Choice ExperimentCandice Chetty-Makkan; C Hoffmann; Salome Charalambous; C Botha; S Ntshuntshe; Nolwazi Nkosi; Hae-Young Kim